Fig. 1

Kaplan Meier plots of clinical development time for multi-indication products, defined as time from pivotal trial initiation to regulatory approval. I – Clinical development time of first vs subsequent indications in the USA. II – Clinical development time of first vs subsequent indications in Europe. III – Clinical development time of first vs subsequent indications in Canada. IV – Clinical development time of first vs subsequent indications in Australia. Abbreviations: EMA – European Medicines Agency, FDA – Food and Drug Administration (USA), TGA – Therapeutic Goods Administration (Australia)